Abstract
Supportive care has traditionally emphasized symptom management and subjective evaluation of quality of life. However, recent advances in molecular biology and molecular genetics are as exciting for supportive care as they are for cytotoxic therapy. Relevant receptor mutations may alter sensitivity to antiemetics or to analgesics while variations in metabolic pathways may affect either efficacy of supportive care agents or toxicity of the chemotherapeutic agents themselves. Altered ligands for various receptors can produce differential effects conducive to better symptom management. Even symptoms such as fatigue and overall outlook may be defined in terms of appropriate enzymatic pathways. Evaluation and application of these advances in basic science are leading directly to new directions in supportive care.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Ahlberg K, Ekman T, Gaston-Johansson F (2004) Levels of fatigue compared to levels of cytokines and hemoglobin during pelvic radiotherapy: a pilot study. Biol Res Nurs 5:203–210
Barnes NM, Bunce KT, Naylor RJ, et al (1991) The actions of fentanyl to inhibit drug induced emesis. Neuropharmacology 30:1073–1083
Burstein SH (1999) The cannabinoid acids: nonpsychoactive derivatives with therapeutic potential. Pharmacol Ther 82:87–96
Innocenti F, Undevia SD, Iyer L, et al (2004) Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 22:1382–1388
Kaiser R, Sezer O, Papies A, et al (2002) Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol 20:2805–2811
Kaiser R, Tremblay PB, Sezer O, et al (2004) Investigation of the association between 5-HT3A receptor gene polymorphisms and efficiency of antiemetic treatment with 5-HT3 receptor antagonists. Pharmacogenetics 14:271–278
Meropol NJ, Somer RA, Gutheil J, et al (2003) Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Oncol 21:1452–1458
Schuller AG, King MA, Zhang J, et al (1999) Retention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1. Nat Neurosci 2:151–156
Sloan JA, McLeod H, Sargent D, et al (2004) Preliminary evidence of relationship between genetic markers and oncology patient quality of life. J Clin Oncol [Suppl] 22:2
Thomas J, Portenoy R, Moehl M, et al (2003) A phase II randomized dose-finding trial of methylnaltrexone for the relief of opioid-induced constipation in hospice patients. Proc ASCO 22:729
Tremblay PB, Kaiser R, Sezer O, et al (2003) Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol 21:2147–2155
Wratten C, Kilmurray J, Nash S, et al (2004) Fatigue during breast radiotherapy and its relationship to biological factors. Int J Radiat Oncol Biol Phys 59:160–167
Author information
Authors and Affiliations
Corresponding author
Additional information
Presented at the 16th MASCC/ISOO International Symposium on Supportive Care in Cancer, held in Miami, FL, USA, in June 2004.
Rights and permissions
About this article
Cite this article
Grunberg, S.M. New directions in supportive care. Support Care Cancer 13, 135–137 (2005). https://doi.org/10.1007/s00520-004-0742-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-004-0742-y